tbuckley/cabot-search huggingface dataset:
Case 37-1989
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Robert H. Brown, Raymond A. Sobel
Journal: New England Journal of Medicine (1989)

Presentation of CaseA 60-year-old man was admitted to the hospital because of cranial-nerve palsies, ataxia, and a left-sided sensory deficit.The patient was well until 5 1/2 months earlier, when he was first admitted to this hospital because of anorexia, nausea, vomiting, "burning" feet, lethargy, and weight loss. He had passed several diarrheal stools daily during the week before admission. The patient was an uncertain historian. He was a custodian in a large building but had felt too ill to work during the month preceding entry. There was a history of paroxysmal atrial fibrillation, which was managed with digoxin . . .
Depression and depressive-like states in preschool-age children in a child development unit
Authors: J H Kashani, J S Ray, G A Carlson
Journal: American Journal of Psychiatry (1984)

A sample of 100 preschool-age children referred to a child development unit were evaluated using DSM-III criteria for symptoms of depression. Only four children (4%) received a diagnosis of possible or definite depression; one of the four children definitely had major depressive disorder. That prevalence rate is much lower than that reported for older children. The findings suggest either that major depressive disorder is rare among preschoolers or that DSM-III criteria are not suitable for diagnosing affective disorders among preschoolers.
Partridge Tureen
Authors: M. Therese Southgate
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An outbreak of measles including nosocomial transmission in Apulia, south-east Italy, January-March 2008 - a preliminary report
Authors: G Caputi, S Tafuri, M Chironna, D Martinelli, A Sallustio, A Falco, C  A Germinario, R Prato, M Quarto
Journal: Eurosurveillance (2008)

Between 7 January and 16 March 2008, 16 cases of measles were reported in the region of Apulia in south-eastern Italy (about four millions inhabitants). This outbreak is currently ongoing: we present here a preliminary report.
The use of problem-oriented medical records in community mental health centers
Authors: G M Vickar, M Herjanic
Journal: American Journal of Psychiatry (1976)

The authors' questionnaire survey of 147 community mental health centers revealed that 36 (24%) were using problem-oriented medical records (POMR), 34 (23%) planned to use them, 23 (16%) were uncertain and 54 (37%) had no considered using them. According to the responses of centers that were using POMR and the authors' experience, the advantages of POMR in psychiatry are similar to their advantages in other specialties, and the difficulties in implementing this system are related to the definition of "problems."
Studies on the Function Canine Heat
Authors: Ralph D. Robertson, Prabhakar Deshpande, Louis Slegel, Stanley W. Jacob
Journal: JAMA (1964)

PRESERVATION of erythrocytes and spermatozoa at near-freezing and below-freezing temperatures has proven of great practical usefulness. Freezing of larger biological units—whole organs or intact organisms—has failed as a means of preservation. With thawing as well as freezing, an incompletely understood set of chemical, physical, and mechanical events causes tissue destruction and death.<sup>1</sup>From presently available information, one can reasonably hypothesize that below zero temperatures per se are not incompatible with survival and that all lethal damage occurs with the transition between unfrozen and frozen states. A corollary of this hypothesis would be that tissue survival would be possible if only a means for instantaneous freezing and rewarming were available. Indeed, the technical impossibility of such rapid freezing has long been recognized as the central obstacle to freezing of more than very minute pieces of tissue. The studies reported here are an attempt to sidestep the freezing dilemma—to reap the
ECDC launches the second version of the EPIS-FWD platform
Authors: C M Gossner
Journal: Eurosurveillance (2013)

Preview this article: ECDC launches the second version of the EPIS-FWD platform, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/18/27/art20517-en-1.gif
MPs question whether adults with personal care budgets get best care
Authors: Jacqui Wise
Journal: BMJ (2016)

Some people in England with personal budgets for social care may not be getting genuinely personalised care, MPs on the Public Accounts Committee have warned.

The committee’s report, Personal Budgets in Social Care , said that personal budgets can potentially transform care and improve the quality of life for most groups of social care users.1 But it warned, “We are not assured that local authorities can fully personalise care while seeking to save money and are concerned that users’ outcomes will …
FRI0377 Fc-Gamma Receptor Polymorphisms Differentially Influence Susceptibility to Systemic Lupus Erythematosus and Disease-Related Manifestations
Authors: M. W.-P. Tsang-A-Sjoe, S.Q. Nagelkerke, I.E. Bultink, J. Geissler, M.W. Tanck, C.E. Tacke, J.E. Ellis, W. Zenz, M. Bijl, J.H. Berden, K. de Leeuw, R.H. Derksen, T.W. Kuipers, A.E. Voskuyl
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Genetic polymorphisms on the locus that encodes low-affinity Fc-gamma receptors (FcγRs) have been associated with systemic lupus erythematosus (SLE). Due to complexity of the locus, the individual contribution of a certain polymorphism to SLE remained largely unclear. <h3>Objectives</h3> To determine relevant FcγR polymorphisms in relation to susceptibility to and disease-related manifestations of SLE. Secondly, to determine functional consequences of found genetic associations. <h3>Methods</h3> Using multiplex ligation-dependent probe amplification, copy number regions (CNRs) and all known functional single nucleotide polymorphisms (SNPs) of FcγRII and FcγRIII were determined in a lupus nephritis-enriched cohort of 266 Dutch Caucasian SLE patients and 919 healthy Caucasian controls. Expression of FcγRs on leukocytes was assessed using flow-cytometry. <h3>Results</h3> In multivariable analysis, low copy number of CNR1 including <i>FCGR3B</i> (OR 2.04, 95% CI 1.29 – 3.23, p=0.002 for 1 vs 2 copies), <i>FCGR2A</i>-131RR (OR 2.00, 95% CI 1.33 – 2.99, p=0.001 for HH vs RR), and the 2B.4 haplotype of <i>FCGR2B</i> (OR 1.59, 95% CI 1.13 – 2.24, p=0.008 for 2B.1/2B.4 vs 2B.4/2B.4) but not <i>FCGR2C-</i>ORF, were significantly and independently associated with susceptibility to SLE. The 2B.4 haplotype was negatively associated with lupus nephritis (OR 0.51, 95% CI 0.28 – 0.91). The 2B.4 haplotype led to surface expression of FcγRIIb on neutrophils and monocytes, but not to increased expression on B-cells, T-cells and NK cells (figure 1). <h3>Conclusions</h3> In a comprehensive study, we show that a low gene copy number encoding FcgRIIIb, a decrease in FcgRIIa affinity, and expression of the inhibitory FcgRIIb on myeloid cells, independently contribute to SLE susceptibility. Interestingly, while the 2B.4 haplotype was associated with susceptibility to SLE, it was also negatively associated with lupus nephritis, one of the major SLE manifestations. Future studies are needed to confirm and further elucidate these findings. <h3>Disclosure of Interest</h3> None declared
Obituary
Authors: Stephen Gold, Neil Smith
Journal: British Journal of Dermatology (1993)

Journal Article Obituary Get access Stephen Gold, Stephen Gold Search for other works by this author on: Oxford Academic Google Scholar Neil Smith Neil Smith Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 128, Issue 6, 1 June 1993, Pages 699–700, https://doi.org/10.1111/j.1365-2133.1993.tb00270.x Published: 01 June 1993
Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Authors: Beverly L. Falcon, Sudhakar Chintharlapalli, Mark T. Uhlik, Bronislaw Pytowski
Journal: Pharmacology & Therapeutics (2016)

Interaction of numerous signaling pathways in endothelial and mesangial cells results in exquisite control of the process of physiological angiogenesis, with a central role played by vascular endothelial growth factor receptor 2 (VEGFR-2) and its cognate ligands. However, deregulated angiogenesis participates in numerous pathological processes. Excessive activation of VEGFR-2 has been found to mediate tissue-damaging vascular changes as well as the induction of blood vessel expansion to support the growth of solid tumors. Consequently, therapeutic intervention aimed at inhibiting the VEGFR-2 pathway has become a mainstay of treatment in cancer and retinal diseases. In this review, we introduce the concepts of physiological and pathological angiogenesis, the crucial role played by the VEGFR-2 pathway in these processes, and the various inhibitors of its activity that have entered the clinical practice. We primarily focus on the development of ramucirumab, the antagonist monoclonal antibody (mAb) that inhibits VEGFR-2 and has recently been approved for use in patients with gastric, colorectal, and lung cancers. We examine in-depth the pre-clinical studies using DC101, the mAb to mouse VEGFR-2, which provided a conceptual foundation for the role of VEGFR-2 in physiological and pathological angiogenesis. Finally, we discuss further clinical development of ramucirumab and the future of targeting the VEGF pathway for the treatment of cancer.
Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.
Authors: I Poizot-Martin, M Giovannini, R Rosello, J R Viallat, J F Sauniere, A M Dalmas, D Genre, C Dhiver, J A Gastaut
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.3.645 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8120565 Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma. I Poizot-MartinxI Poizot-MartinSearch for articles by this author , M GiovanninixM GiovanniniSearch for articles by this author , R RoselloxR RoselloSearch for articles by this author , J R ViallatxJ R ViallatSearch for articles by this author , J F SaunierexJ F SauniereSearch for articles by this author , A M DalmasxA M DalmasSearch for articles by this author , D GenrexD GenreSearch for articles by this author , C DhiverxC DhiverSearch for articles by this author , J A GastautxJ A GastautSearch for articles by this author Show More https://doi.org/10.1200/JCO.1994.12.3.645 PDF "Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.." Journal of Clinical Oncology, 12(3), p. 645© 1994 by American Society of Clinical Oncology
AB0229 Serum Concentrations of Vascular Endothelial Growth Factor Serum and Ultrasound Score of 7 Joints in Rheumatoid Arthritis Patients
Authors: A. Reyes-Suárez, L.T. Becerril-Mendoza, G.E. Lugo-Zamudio, P. Rodríguez-Henríquez, R.I. Castillo-Castañeda, J. Toscano-Garibay, J.J. Flores-Estrada, R.E. Barbosa-Cobos
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The major angiogenic mediator in Rheumatoid Arthritis (RA) is the vascular endothelial growth factor (VEGF), which correlates with disease activity. High frecuency ultrasonography and power Doppler are sensitive tools for evaluate synovial vascularization. <h3>Objectives</h3> To evaluate correlation of DAS28-CRP, VEGF and German ultrasound score of 7 joints (GUS7). <h3>Methods</h3> We included 29 RA patients, 8 patients in remission, 3 with mild activity, 14 with moderate activity and 4 with severe activity. Clinical evaluation included DAS28-CRP assessment and serum VEGF levels by ELISA where obtained; 48 hours after the GUS7 was realized with a Esaote MyLab 25 device with a 18 MHz linear transducer in the dominants hand and foot; synovitis grayscale and power Doppler signal (DP) were evaluated in a semiquantitative scale. <h3>Results</h3> The trial involved 28 female and 1 male, average age 44 years. The median DAS28-CRP was 3.78, PCR 0.07 mg/L and VEGF 691.17 pg /L. Evaluation by GUS7 median DP was 0 (positive activity in one or more joints in 12 patients) and median overall score was 8. DAS28-CRP positive correlation was found with VEGF 0.441 (p&lt;0.05). <h3>Conclusions</h3> Elevations of serum VEGF levels according to RA activity by DAS28-CRP are similar in those reported in previous studies. No statistical significance was found during correlation between VEGF and Power Doppler, unlike those reported by other authors. Although this is the first study that points to the association between VEGF and GUS7, the negative correlation between clinical and ultrasonographic findings in our study may be due to non-controlled factors that influentiates Power Doppler signal. <h3>References</h3> Ewa M Paleolog. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002, 4 (suppl 3):S81-S90. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001, 280:C1358-1366. Zoltán Szekanecz, Alisa E. Koch. Angiogenesis and its targeting in rheumatoid arthritis. Vascular Pharmacology 51 (2009): 1–7. Brennan, F., Beech, J. Update on cytokines in rheumatoid arthritis. Curr. Opin. Rheumatol. 2007: 19, 296–301. Liu, L.X., Lu, H., Luo, Y., Date, T., Belanger, A.J., Vincent, K.A., Akita, G.Y., Goldberg, M.,Cheng, S.H., Gregory, R.J., Jiang, C. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem. Biophys., 2002 Res. Commun. 291, 908–914. <h3>Disclosure of Interest</h3> None declared
A Radiotracer Strategy to Quantify PARP-1 Expression <i>In Vivo</i> Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Authors: Mehran Makvandi, Kuiying Xu, Brian P. Lieberman, Redmond-Craig Anderson, Samuel Sander Effron, Harrison D. Winters, Chenbo Zeng, Elizabeth S. McDonald, Daniel A. Pryma, Roger A. Greenberg, Robert H. Mach
Journal: Cancer Research (2016)

Despite the availability of PARP inhibitors for cancer therapy, a biomarker to clearly stratify patients for selection of this treatment remains lacking. Here we describe a radiotracer-based method that addresses this issue, using the novel compound [(125)I] KX1: as a PARP-1-selective radiotracer that can accurately measure PARP-1 expression in vitro and in vivo The pharmacologic properties of the PARP radiotracer [(125)I] KX1: was characterized in multiple cell lines where single-agent sensitivity was correlated with [(125)I] KX1: binding to PARP-1. In vivo evaluation of [(125)I] KX1: verified in vitro results, validating PARP radiotracers to define PARP-1 enzyme expression as an in vivo biomarker. Notably, PARP-1 expression as quantified by [(125)I] KX1: correlated positively with the cytotoxic sensitivity of cell lines evaluated with PARP inhibitors. Overall, our results defined a novel technology with the potential to serve as a companion diagnostic to identify patients most likely to respond therapeutically to a PARP inhibitor. Cancer Res; 76(15); 4516-24. ©2016 AACR.
Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses
Authors: Katrin D Mayer-Barber, Bo Yan
Journal: Cellular and Molecular Immunology (2016)

Over the past decades the notion of 'inflammation' has been extended beyond the original hallmarks of rubor (redness), calor (heat), tumor (swelling) and dolor (pain) described by Celsus. We have gained a more detailed understanding of the cellular players and molecular mediators of inflammation which is now being applied and extended to areas of biomedical research such as cancer, obesity, heart disease, metabolism, auto-inflammatory disorders, autoimmunity and infectious diseases. Innate cytokines are often central components of inflammatory responses. Here, we discuss how the type I interferon and interleukin-1 cytokine pathways represent distinct and specialized categories of inflammatory responses and how these key mediators of inflammation counter-regulate each other.
OC-062 Lung ultrasonography as a direct measure of evolving respiratory dysfunction and disease severity in patients with acute pancreatitis
Authors: C Skouras, ZA Davis, J Sharkey, RW Parks, OJ Garden, JT Murchison, DJ Mole
Journal: Gut (2015)

<h3>Introduction</h3> Lung ultrasonography has been proposed as a useful method for diagnosing alveolar-interstitial syndrome, based on the detection and quantification of comet-tail artefacts. The aim of the present study was to investigate its value in the diagnosis of respiratory dysfunction and severity stratification in patients with acute pancreatitis (AP). <h3>Method</h3> This prospective pilot study received ethical committee approval, and written informed consent was obtained from all participants or their surrogates. Between September and December 2013, 41 patients (median age: 59.1 years; 21 males) presenting to the Royal Infirmary of Edinburgh with a potential diagnosis of AP were recruited. Each participant underwent lung ultrasonography and the number of comet-tail artefacts was linked with contemporaneous, prospectively collected clinical data. Patient group comparisons, areas under the curve (AUC) and respective measures of diagnostic accuracy were examined in relation to: i. Respiratory dysfunction status, ii. Disease severity, as defined by the revised Atlanta criteria for AP, iii. C-Reactive Protein contemporaneous with the scan, and iv. Maximum CRP value of the first week of admission. The results were analysed for all lung quadrants, all quadrants except for the lower lateral, and upper quadrants alone. <h3>Results</h3> A greater number of comet tails were evident in patients with respiratory dysfunction, those with severe disease and when contemporaneous and maximum CRP were above 100 mg/L (P = 0.021; P &lt; 0.001; P = 0.048 and P = 0.003, respectively). The AUC was greater for the method examining upper lung quadrants alone, when respiratory dysfunction and severity were used as the parameter of interest (AUC = 0.783, 95% C. I.: 0.544–0.962, and AUC = 0.996, 95% C. I.: 0.982–1.000, respectively). Conversely, examining all lung quadrants except for the lower lateral provided the best results for contemporaneous and maximum CRP (AUC = 0.708, 95% C. I.: 0.510–0.883, and AUC = 0.800, 95% C. I.: 0.640–0.929). <h3>Conclusion</h3> Ultrasonography of non-dependant lung parenchyma can reliably detect evolving respiratory dysfunction in acute pancreatitis and is potentially useful for severity stratification. This simple, easily repeatable bedside test deserves further validation in a larger cohort. <h3>Disclosure of interest</h3> None Declared.
SP0071 GCA and PMR:Steroids or Bust?
Authors: B. Dasgupta
Journal: Annals of the Rheumatic Diseases (2015)

There is an unmet need for safer and more efficacious treatment of GCA and PMR. Up to 50-60% of patients may experience flares on glucocorticoids (GC) and GC resistant cases are seen especially in the context of large vessel vasculitis. BSR guidelines advocate initial prednisolone 15-20 mg daily and 2015 ACR/EULAR guidelines for the management of PMR recommend minimum effective GC dose within a range of 12.5–25 mg prednisone equivalent daily as initial treatment. Dose tapering schedules in PMR should be individualized, with regular monitoring of disease activity, laboratory markers and adverse events (Figure 3). Intramuscular methylprednisolone given every 3-4 weeks is an effective alternate treatment strategy in patients where a lower cumulative GC dose is desirable. For GCA, guidelines recommend an initial dose of prednisone equivalent of 40–60 mg/day and GC dose tapering should be individualized according to the clinical course. Treatment with intravenous methylprednisolone pulse therapy (usually 1 g daily for 3 consecutive days) is recommended for patients with severe ischemic manifestations such as visual disturbance, cerebrovascular accidents or symptomatic, progressive large artery stenosis of the extremities. A limited number of RCTs support the adjunctive use of MTX as GC sparing agent in PMR on an individualized basis. Early use of methotrexate may be considered in patients with a high risk for relapses and/or GC-induced adverse events. MTX also has benefits in GCA and a meta-analysis of three MTX trials revealed a marginal reduction in risk for the first relapse, higher rates of GC-free remission and lower cumulative GC doses. MTX is included in EULAR and British treatment recommendations as adjunctive therapy. RCTs of other conventional DMARDs such as azathioprine, cyclosporine A and dapsone, as well as tumor necrosis factor-alpha (TNF-a) blocking agents, have been disappointing, whereas published case series on the successful use of leflunomide and tocilizumab in treatment resistant cases with PMR and GCA are promising. The GiACTA trial is an ongoing multicenter trial investigating the efficacy of tocilizumab in maintaining remission in GCA. RCTs completed or ongoing include safety and efficacy of secukinumab (anti-IL17A) and canakinumab (anti-IL1b) in PMR, anti-IL-1b antibody gevokizumab in GCA, with results expected in the near future. <h3>Disclosure of Interest</h3> B. Dasgupta Grant/research support from: Napp, Consultant for: GSK,Roche,Servier,Merck